Journal of Clinical Medicine (Oct 2022)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?

  • Katarzyna Wołos-Kłosowicz,
  • Wojciech Matuszewski,
  • Joanna Rutkowska,
  • Katarzyna Krankowska,
  • Elżbieta Bandurska-Stankiewicz

DOI
https://doi.org/10.3390/jcm11206183
Journal volume & issue
Vol. 11, no. 20
p. 6183

Abstract

Read online

Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM), estimated to affect approximately one-third of the diabetic population, and the most common cause of preventable vision loss. The available treatment options focus on the late stages of this complication, while in the early stages there is no dedicated treatment besides optimizing blood pressure, lipid and glycemic control; DR is still lacking effective preventive methods. glucagon-like peptide 1 receptor agonists (GLP-1 Ras) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors have a proven effect in reducing risk factors of DR and numerous experimental and animal studies have strongly established its retinoprotective potential. Both drug groups have the evident potential to become a new therapeutic option for the prevention and treatment of diabetic retinopathy and there is an urgent need for further comprehensive clinical trials to verify whether these findings are translatable to humans.

Keywords